Capital Counsel’s Pfizer PFE Stock Holding History

Capital Counsel’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,441	Closed	-$209K	–	61
2017 Q1	$209K	Sell	6,441 -1,348	-17%	-$42.5K	0.02%	62
2016 Q4	$240K	Hold	7,789	–	–	0.02%	56
2016 Q3	$250K	Buy	+7,789	New	+$260K	0.02%	55
2016 Q1	–	Sell	-22,777	Closed	-$698K	–	106
2015 Q4	$698K	Buy	22,777 +9,533	+72%	+$300K	0.04%	64
2015 Q3	$395K	Hold	13,244	–	–	0.02%	83
2015 Q2	$421K	Buy	13,244 +1,834	+16%	+$59.8K	0.02%	91
2015 Q1	$377K	Hold	11,410	–	–	0.02%	100
2014 Q4	$337K	Sell	11,410 -606	-5%	-$17.4K	0.02%	101
2014 Q3	$337K	Buy	12,016 +606	+5%	+$17K	0.02%	97
2014 Q2	$321K	Sell	11,410 -426	-4%	-$12.1K	0.02%	107
2014 Q1	$361K	Sell	11,836 -3,162	-21%	-$94.3K	0.02%	99
2013 Q4	$436K	Buy	14,998 +1,410	+10%	+$41K	0.02%	93
2013 Q3	$370K	Buy	13,588 +577	+4%	+$15.7K	0.02%	93
2013 Q2	$346K	Buy	+13,011	New	+$359K	0.02%	93

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Counsel's PFE Position: Q2 2017 in Review

Capital Counsel sold out of Pfizer (PFE) in Q2 2017, closing a stake of 6,441 shares — an estimated $209K sold.

Capital Counsel first reported a position in PFE in Q2 2013 and held it in 14 quarters. The position peaked at $698K in Q4 2015. 2,050 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

Capital Counsel reported no remaining Pfizer position as of Q2 2017 after selling out during the quarter.
Capital Counsel sold 6,441 Pfizer shares in Q2 2017, an estimated $209K.
Capital Counsel first reported a position in Pfizer in Q2 2013 and held it in 14 quarters.
Capital Counsel's Pfizer position peaked at $698K in Q4 2015.
2,050 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on Capital Counsel's 13F filing for Q2 2017, filed 10 Aug 2017.